Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.

NCT07679269 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07679269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07679269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib.
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 15, 2026
Completion date
April 20, 2032
Enrollment
51 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms (including advanced or metastatic breast cancer with pik3ca mutation), pik3ca-related overgrowth spectrum (pros)